Abcellera Biologics Inc (ABCL)

$4.02

+0.05

(+1.26%)▲

Live

Insights on Abcellera Biologics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 6.59M → 9.17M (in $), with an average increase of 28.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -28.61M → -47.15M (in $), with an average decrease of 64.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 95.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 333.9%

Performance

  • $3.98
    $4.24
    $4.02
    downward going graph

    1.0%

    Downside

    Day's Volatility :6.13%

    Upside

    5.19%

    downward going graph
  • $3.79
    $8.05
    $4.02
    downward going graph

    5.72%

    Downside

    52 Weeks Volatility :52.92%

    Upside

    50.06%

    downward going graph

Returns

PeriodAbcellera Biologics IncSector (Health Care)Index (Russel 2000)
3 Months
-24.52%
1.9%
0.0%
6 Months
-10.79%
10.7%
0.0%
1 Year
-44.63%
4.6%
-1.1%
3 Years
-87.44%
14.2%
-22.1%

Highlights

Market Capitalization
1.2B
Book Value
$3.96
Earnings Per Share (EPS)
-0.51
Wall Street Target Price
15.38
Profit Margin
0.0%
Operating Margin TTM
-719.61%
Return On Assets TTM
-9.79%
Return On Equity TTM
-12.27%
Revenue TTM
38.0M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
-57.4%
Gross Profit TTM
311.1M
EBITDA
-212.8M
Diluted Eps TTM
-0.51
Quarterly Earnings Growth YOY
0.46
EPS Estimate Current Year
-0.64
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.13
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Abcellera Biologics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 282.59%

Current $4.02
Target $15.38

Company Financials

FY18Y/Y Change
Revenue
8.8M
-
Net Income
309.0K
-
Net Profit Margin
3.5%
-
FY19Y/Y Change
Revenue
11.6M
↑ 31.49%
Net Income
-2.4M
↓ 883.14%
Net Profit Margin
-20.84%
↓ 24.34%
FY20Y/Y Change
Revenue
233.2M
↑ 1907.96%
Net Income
118.9M
↓ 5014.19%
Net Profit Margin
51.0%
↑ 71.84%
FY21Y/Y Change
Revenue
11.6M
↓ 95.02%
Net Income
-2.2M
↓ 101.86%
Net Profit Margin
-19.04%
↓ 70.04%
FY22Y/Y Change
Revenue
485.4M
↑ 4080.53%
Net Income
158.5M
↓ 7270.55%
Net Profit Margin
32.66%
↑ 51.7%
FY23Y/Y Change
Revenue
38.0M
↓ 92.17%
Net Income
-146.4M
↓ 192.35%
Net Profit Margin
-385.0%
↓ 417.66%
Q3 FY22Q/Q Change
Revenue
101.4M
↑ 120.8%
Net Income
26.6M
↓ 492.39%
Net Profit Margin
26.26%
↑ 41.04%
Q4 FY22Q/Q Change
Revenue
21.5M
↓ 78.75%
Net Income
-29.9M
↓ 212.28%
Net Profit Margin
-138.75%
↓ 165.01%
Q1 FY23Q/Q Change
Revenue
12.2M
↓ 43.41%
Net Income
-40.1M
↑ 34.18%
Net Profit Margin
-328.99%
↓ 190.24%
Q2 FY23Q/Q Change
Revenue
10.1M
↓ 17.52%
Net Income
-30.5M
↓ 23.89%
Net Profit Margin
-303.58%
↑ 25.41%
Q3 FY23Q/Q Change
Revenue
6.6M
↓ 34.38%
Net Income
-28.6M
↓ 6.28%
Net Profit Margin
-433.55%
↓ 129.97%
Q4 FY23Q/Q Change
Revenue
9.2M
↑ 39.1%
Net Income
-47.2M
↑ 64.8%
Net Profit Margin
-513.67%
↓ 80.12%
FY18Y/Y Change
Total Assets
21.5M
-
Total Liabilities
9.9M
-
FY19Y/Y Change
Total Assets
23.5M
↑ 9.29%
Total Liabilities
13.2M
↑ 33.93%
FY20Y/Y Change
Total Assets
1.0B
↑ 4181.05%
Total Liabilities
175.0M
↑ 1222.37%
FY21Y/Y Change
Total Assets
1.3B
↑ 31.13%
Total Liabilities
292.8M
↑ 67.31%
FY22Y/Y Change
Total Assets
1.5B
↑ 16.86%
Total Liabilities
307.6M
↑ 5.05%
FY23Y/Y Change
Total Assets
1.5B
↓ 3.43%
Total Liabilities
335.8M
↑ 9.15%
Q3 FY22Q/Q Change
Total Assets
1.6B
↓ 2.6%
Total Liabilities
302.2M
↓ 20.66%
Q4 FY22Q/Q Change
Total Assets
1.5B
↓ 0.74%
Total Liabilities
307.6M
↑ 1.78%
Q1 FY23Q/Q Change
Total Assets
1.5B
↓ 2.79%
Total Liabilities
289.4M
↓ 5.92%
Q2 FY23Q/Q Change
Total Assets
1.5B
↑ 2.62%
Total Liabilities
342.3M
↑ 18.28%
Q3 FY23Q/Q Change
Total Assets
1.5B
↓ 1.62%
Total Liabilities
329.4M
↓ 3.78%
Q4 FY23Q/Q Change
Total Assets
1.5B
↓ 1.59%
Total Liabilities
335.8M
↑ 1.93%
FY18Y/Y Change
Operating Cash Flow
3.6M
-
Investing Cash Flow
-5.3M
-
Financing Cash Flow
12.2M
-
FY19Y/Y Change
Operating Cash Flow
2.7M
↓ 24.44%
Investing Cash Flow
-5.8M
↑ 8.91%
Financing Cash Flow
194.8K
↓ 98.4%
FY20Y/Y Change
Operating Cash Flow
22.7M
↑ 742.33%
Investing Cash Flow
-119.8M
↑ 1972.35%
Financing Cash Flow
683.7M
↑ 350804.4%
FY21Y/Y Change
Operating Cash Flow
244.6M
↑ 977.94%
Investing Cash Flow
-332.2M
↑ 177.38%
Financing Cash Flow
-3.9M
↓ 100.57%
FY22Y/Y Change
Operating Cash Flow
277.4M
↑ 13.4%
Investing Cash Flow
-352.6M
↑ 6.13%
Financing Cash Flow
-1.6M
↓ 58.11%
Q3 FY22Q/Q Change
Operating Cash Flow
-126.8M
↓ 146.44%
Investing Cash Flow
-282.0M
↑ 936.86%
Financing Cash Flow
-19.0K
↓ 101.62%
Q4 FY22Q/Q Change
Operating Cash Flow
30.9M
↓ 124.38%
Investing Cash Flow
-17.1M
↓ 93.95%
Financing Cash Flow
349.0K
↓ 1936.84%
Q1 FY23Q/Q Change
Operating Cash Flow
-44.1M
↓ 242.54%
Investing Cash Flow
-149.6M
↑ 776.8%
Financing Cash Flow
-458.0K
↓ 231.23%
Q2 FY23Q/Q Change
Operating Cash Flow
19.9M
↓ 145.17%
Investing Cash Flow
-34.4M
↓ 77.01%
Financing Cash Flow
419.0K
↓ 191.48%
Q3 FY23Q/Q Change
Operating Cash Flow
-106.0K
↓ 100.53%
Investing Cash Flow
-12.8M
↓ 62.82%
Financing Cash Flow
6.6M
↑ 1482.34%

Technicals Summary

Sell

Neutral

Buy

Abcellera Biologics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abcellera Biologics Inc
Abcellera Biologics Inc
-13.32%
-10.79%
-44.63%
-87.44%
-93.26%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
9.62%
21.65%
86.62%
134.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abcellera Biologics Inc
Abcellera Biologics Inc
12.33
NA
NA
-0.64
-0.12
-0.1
NA
3.96
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abcellera Biologics Inc
Abcellera Biologics Inc
Buy
$1.2B
-93.26%
12.33
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
134.62%
28.81
36.68%

Institutional Holdings

  • Baillie Gifford & Co Limited.

    8.21%

  • Baker Bros Advisors LP

    7.82%

  • ING Investment Management LLC

    3.63%

  • Capital World Investors

    2.85%

  • Credit Suisse First Boston (CSFB)

    1.56%

  • Orbimed Advisors, LLC

    1.43%

Company Information

abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’

Organization
Abcellera Biologics Inc
Employees
586
CEO
Dr. Carl L.G. Hansen Ph.D.
Industry
Healthcare

Discover More

FAQs